Cefepime combined with amoxicillin/clavulanic acid: A new choice for the KPC-producing K. pneumoniae infection

International Journal of Infectious Diseases

Volumn 38, Issue , 2015, Pages 108-114

  Ji, Shujuan ^a   Lv, Fangfang ^a   Du, Xiaoxing ^a   Wei, Zeqing ^b   Fu, Ying ^a   Mu, Xinli ^a   Jiang, Yan ^a   Yu, Yunsong ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Amoxicillin clavulanic acid; Cefepime; Klebsiella pneumoniae; KPC; Prospective study; Tigecycline

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFEPIME; CEFOPERAZONE PLUS SULBACTAM; FOSFOMYCIN; LEVOFLOXACIN; MEROPENEM; TIGECYCLINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE; CEPHALOSPORIN DERIVATIVE; MINOCYCLINE;

ABDOMINAL INFECTION; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTERIAL CLEARANCE; BLOODSTREAM INFECTION; CHINA; CONTROLLED STUDY; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HEALTHCARE ASSOCIATED INFECTION; HUMAN; IN VITRO STUDY; INFECTION RISK; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; NONHUMAN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT INFECTION; ADULT; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; COMBINATION DRUG THERAPY; ECONOMICS; ENZYMOLOGY; KLEBSIELLA INFECTIONS; MICROBIOLOGY; MIDDLE AGED;

ADULT; AGED; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CEPHALOSPORINS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; MINOCYCLINE;

EID: 84940190043     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2015.07.024     Document Type: Article

References (26)

1. Qureshi Z.A., Paterson D.L., Potoski B.A., Kilayko M.C., Sandovsky G., Sordillo E., et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrobial agents and chemotherapy 2012, 56:2108-2113.
2. Souli M., Kontopidou F.V., Papadomichelakis E., Galani I., Armaganidis A., Giamarellou H. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek University Hospital. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2008, 46:847-854.
3. Nordmann P., Poirel L. The difficult-to-control spread of carbapenemase producers in Enterobacteriaceae worldwide. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2014.
4. Peleg A.Y., Franklin C., Bell J.M., Spelman D.W. Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2005, 41:1549-1556.
5. Kumarasamy K.K., Toleman M.A., Walsh T.R., Bagaria J., Butt F., Balakrishnan R., et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. The Lancet infectious diseases 2010, 10:597-602.
6. Munoz-Price L.S., Poirel L., Bonomo R.A., Schwaber M.J., Daikos G.L., Cormican M., et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. The Lancet infectious diseases 2013, 13:785-796.
7. Wei Z.Q., Du X.X., Yu Y.S., Shen P., Chen Y.G., Li L.J. Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. Antimicrobial agents and chemotherapy 2007, 51:763-765.
8. Endimiani A., Patel G., Hujer K.M., Swaminathan M., Perez F., Rice L.B., et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrobial agents and chemotherapy 2010, 54:526-529.
9. Shen P., Wei Z., Jiang Y., Du X., Ji S., Yu Y., et al. Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China. Antimicrobial agents and chemotherapy 2009, 53:4333-4338.
10. Pournaras S., Vrioni G., Neou E., Dendrinos J., Dimitroulia E., Poulou A., et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. International journal of antimicrobial agents 2011, 37:244-247.
11. Tumbarello M., Viale P., Viscoli C., Trecarichi E.M., Tumietto F., Marchese A., et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2012, 55:943-950.
12. Michail G., Labrou M., Pitiriga V., Manousaka S., Sakellaridis N., Tsakris A., et al. Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model. Antimicrobial agents and chemotherapy 2013, 57:6028-6033.
13. Qi Y., Wei Z., Ji S., Du X., Shen P., Yu Y. ST11, the dominant clone of KPC-producing Klebsiella pneumoniae in China. The Journal of antimicrobial chemotherapy 2011, 66:307-312.
14. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobail Susceptibility Testing: Twentieth Informational Supplement M100-S20. CLSI, Wayne, PA,USA. (2013).
15. EUCAST (2011) Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3, March 2011. Available at . http://www.eucast.org/.
16. Pharmaceuticals. W. Typacil Product Insert. (19 December 2006, date last accessed). http://www.typacil.com/.
17. Ji J., Du X., Chen Y., Fu Y., Wang H., Yu Y. In vitro activity of sulbactam in combination with imipenem, meropenem, panipenem or cefoperazone against clinical isolates of Acinetobacter baumannii. International journal of antimicrobial agents 2013, 41:400-401.
18. Daikos G.L., Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2011, 17:1135-1141.
19. Yahav D., Lador A., Paul M., Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. The Journal of antimicrobial chemotherapy 2011, 66:1963-1971.
20. Gardiner D., Dukart G., Cooper A., Babinchak T. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2010, 50:229-238.
21. Hirsch E.B., Tam V.H. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. The Journal of antimicrobial chemotherapy 2010, 65:1119-1125.
22. Dubrovskaya Y., Chen T.Y., Scipione M.R., Esaian D., Phillips M.S., Papadopoulos J., et al. Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. Antimicrobial agents and chemotherapy 2013, 57:5394-5397.
23. Yahav D., Paul M., Fraser A., Sarid N., Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. The Lancet infectious diseases 2007, 7:338-348.
24. Chopra T., Marchaim D., Veltman J., Johnson P., Zhao J.J., Tansek R., et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrobial agents and chemotherapy 2012, 56:3936-3942.
25. Cardile A.P., Briggs H., Burguete S.R., Herrera M., Wickes B.L., Jorgensen J.H. Treatment of KPC-2 Enterobacter cloacae empyema with cefepime and levofloxacin. Diagnostic microbiology and infectious disease 2014, 78:199-200.
26. Du X., Fu Y., Yu Y. Tigecycline treatment of infection caused by KPC-producing Escherichia coli in a pediatric patient. Annals of clinical microbiology and antimicrobials 2013, 12:19.